The role of thioredoxin reductase 1 in melanoma metabolism and metastasis

Pamela Cassidy, Matthew Honeggar, Robyn L. Poerschke, Karen White, Scott R. Florell, Robert H I Andtbacka, Joycelyn Tross, Madeleine Anderson, Sancy Leachman, Philip J. Moos

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although significant progress has been made in targeted and immunologic therapeutics for melanoma, many tumors fail to respond, and most eventually progress when treated with the most efficacious targeted combination therapies thus far identified. Therefore, alternative approaches that exploit distinct melanoma phenotypes are necessary to develop new approaches for therapeutic intervention. Tissue microarrays containing human nevi and melanomas were used to evaluate levels of the antioxidant protein thioredoxin reductase 1 (TR1), which was found to increase as a function of disease progression. Melanoma cell lines revealed metabolic differences that correlated with TR1 levels. We used this new insight to design a model treatment strategy that creates a synthetic lethal interaction wherein targeting TR1 sensitizes melanoma to inhibition of glycolytic metabolism, resulting in a decrease in metastases in vivo. This approach holds the promise of a new clinical therapeutic strategy, distinct from oncoprotein inhibition.

Original languageEnglish (US)
Pages (from-to)685-695
Number of pages11
JournalPigment Cell and Melanoma Research
Volume28
Issue number6
DOIs
StatePublished - Nov 1 2015

Fingerprint

Thioredoxin Reductase 1
Metabolism
Melanoma
Neoplasm Metastasis
Enzyme inhibition
Oncogene Proteins
Nevi and Melanomas
Microarrays
Tumors
Therapeutics
Antioxidants
Cells
Tissue
Disease Progression
Phenotype
Cell Line
Proteins
Neoplasms

Keywords

  • Immunohistochemistry
  • Melanoma
  • Metabolism
  • Mitochondria
  • Thioredoxinreductase

ASJC Scopus subject areas

  • Dermatology
  • Oncology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cassidy, P., Honeggar, M., Poerschke, R. L., White, K., Florell, S. R., Andtbacka, R. H. I., ... Moos, P. J. (2015). The role of thioredoxin reductase 1 in melanoma metabolism and metastasis. Pigment Cell and Melanoma Research, 28(6), 685-695. https://doi.org/10.1111/pcmr.12398

The role of thioredoxin reductase 1 in melanoma metabolism and metastasis. / Cassidy, Pamela; Honeggar, Matthew; Poerschke, Robyn L.; White, Karen; Florell, Scott R.; Andtbacka, Robert H I; Tross, Joycelyn; Anderson, Madeleine; Leachman, Sancy; Moos, Philip J.

In: Pigment Cell and Melanoma Research, Vol. 28, No. 6, 01.11.2015, p. 685-695.

Research output: Contribution to journalArticle

Cassidy, P, Honeggar, M, Poerschke, RL, White, K, Florell, SR, Andtbacka, RHI, Tross, J, Anderson, M, Leachman, S & Moos, PJ 2015, 'The role of thioredoxin reductase 1 in melanoma metabolism and metastasis', Pigment Cell and Melanoma Research, vol. 28, no. 6, pp. 685-695. https://doi.org/10.1111/pcmr.12398
Cassidy P, Honeggar M, Poerschke RL, White K, Florell SR, Andtbacka RHI et al. The role of thioredoxin reductase 1 in melanoma metabolism and metastasis. Pigment Cell and Melanoma Research. 2015 Nov 1;28(6):685-695. https://doi.org/10.1111/pcmr.12398
Cassidy, Pamela ; Honeggar, Matthew ; Poerschke, Robyn L. ; White, Karen ; Florell, Scott R. ; Andtbacka, Robert H I ; Tross, Joycelyn ; Anderson, Madeleine ; Leachman, Sancy ; Moos, Philip J. / The role of thioredoxin reductase 1 in melanoma metabolism and metastasis. In: Pigment Cell and Melanoma Research. 2015 ; Vol. 28, No. 6. pp. 685-695.
@article{6872707c0670488797afa980af971711,
title = "The role of thioredoxin reductase 1 in melanoma metabolism and metastasis",
abstract = "Although significant progress has been made in targeted and immunologic therapeutics for melanoma, many tumors fail to respond, and most eventually progress when treated with the most efficacious targeted combination therapies thus far identified. Therefore, alternative approaches that exploit distinct melanoma phenotypes are necessary to develop new approaches for therapeutic intervention. Tissue microarrays containing human nevi and melanomas were used to evaluate levels of the antioxidant protein thioredoxin reductase 1 (TR1), which was found to increase as a function of disease progression. Melanoma cell lines revealed metabolic differences that correlated with TR1 levels. We used this new insight to design a model treatment strategy that creates a synthetic lethal interaction wherein targeting TR1 sensitizes melanoma to inhibition of glycolytic metabolism, resulting in a decrease in metastases in vivo. This approach holds the promise of a new clinical therapeutic strategy, distinct from oncoprotein inhibition.",
keywords = "Immunohistochemistry, Melanoma, Metabolism, Mitochondria, Thioredoxinreductase",
author = "Pamela Cassidy and Matthew Honeggar and Poerschke, {Robyn L.} and Karen White and Florell, {Scott R.} and Andtbacka, {Robert H I} and Joycelyn Tross and Madeleine Anderson and Sancy Leachman and Moos, {Philip J.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/pcmr.12398",
language = "English (US)",
volume = "28",
pages = "685--695",
journal = "Pigment Cell and Melanoma Research",
issn = "1755-1471",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The role of thioredoxin reductase 1 in melanoma metabolism and metastasis

AU - Cassidy, Pamela

AU - Honeggar, Matthew

AU - Poerschke, Robyn L.

AU - White, Karen

AU - Florell, Scott R.

AU - Andtbacka, Robert H I

AU - Tross, Joycelyn

AU - Anderson, Madeleine

AU - Leachman, Sancy

AU - Moos, Philip J.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Although significant progress has been made in targeted and immunologic therapeutics for melanoma, many tumors fail to respond, and most eventually progress when treated with the most efficacious targeted combination therapies thus far identified. Therefore, alternative approaches that exploit distinct melanoma phenotypes are necessary to develop new approaches for therapeutic intervention. Tissue microarrays containing human nevi and melanomas were used to evaluate levels of the antioxidant protein thioredoxin reductase 1 (TR1), which was found to increase as a function of disease progression. Melanoma cell lines revealed metabolic differences that correlated with TR1 levels. We used this new insight to design a model treatment strategy that creates a synthetic lethal interaction wherein targeting TR1 sensitizes melanoma to inhibition of glycolytic metabolism, resulting in a decrease in metastases in vivo. This approach holds the promise of a new clinical therapeutic strategy, distinct from oncoprotein inhibition.

AB - Although significant progress has been made in targeted and immunologic therapeutics for melanoma, many tumors fail to respond, and most eventually progress when treated with the most efficacious targeted combination therapies thus far identified. Therefore, alternative approaches that exploit distinct melanoma phenotypes are necessary to develop new approaches for therapeutic intervention. Tissue microarrays containing human nevi and melanomas were used to evaluate levels of the antioxidant protein thioredoxin reductase 1 (TR1), which was found to increase as a function of disease progression. Melanoma cell lines revealed metabolic differences that correlated with TR1 levels. We used this new insight to design a model treatment strategy that creates a synthetic lethal interaction wherein targeting TR1 sensitizes melanoma to inhibition of glycolytic metabolism, resulting in a decrease in metastases in vivo. This approach holds the promise of a new clinical therapeutic strategy, distinct from oncoprotein inhibition.

KW - Immunohistochemistry

KW - Melanoma

KW - Metabolism

KW - Mitochondria

KW - Thioredoxinreductase

UR - http://www.scopus.com/inward/record.url?scp=84944516323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944516323&partnerID=8YFLogxK

U2 - 10.1111/pcmr.12398

DO - 10.1111/pcmr.12398

M3 - Article

C2 - 26184858

AN - SCOPUS:84944516323

VL - 28

SP - 685

EP - 695

JO - Pigment Cell and Melanoma Research

JF - Pigment Cell and Melanoma Research

SN - 1755-1471

IS - 6

ER -